Rougier.

Methods	Multicentre randomised controlled trial. Generation of allocation schedule truly random.
Participants	166 patients with unresectable hepatic metastases from primary colorectal cancer. Primary tumour had been resected. Hepatic metastases unresectable. No evidence of extrahepatic disease or ascites. WHO perfomance status 0‐2. Less than 75% hepatic involvement with tumour. Specified bilirubin level for inclusion.
Interventions	Hepatic artery infusion of Floxuridine (0.3mg/kg/day) for 14 days every 4 weeks vs Observation or systemic bolus 5‐FU infusion (500mg/m2/day) for 5 days every 4 weeks
Outcomes	Survival, Progression, Tumour response, Complications, Toxicity
Notes	24/82 in treatment group and 41/82 in control group had systemic chemotherapy Analysis by intention to treat
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Low risk	A ‐ Adequate